This article was originally published in The Gray Sheet
Completes $12.5 mil. private placement of 4% convertible preferred stock. The funds strengthen the imaging and therapeutic product maker's financial position as it continues to boost marketing efforts for CEA-Scan (arcitumomab) in the U.S. and Europe, and for LeukoScan (sulesomab) in Europe. Plans for U.S. marketing of LeukoScan, pending FDA approval, are also under way. Subject to certain conditions, the firm has an option for up to an additional $7.5 mil. convertible preferred stock offering
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.